Statistical comparisons revealed that CBNS users had significantly lower risks of developing nonexudative/advanced AMD or geographic atrophy, blindness, and the need for intravitreal anti-VEGF therapy compared with non-users. Here, VEGFA is linked to age-related macular degeneration.